SOPs for BA-BE Studies V 2.0

To define the process for planning, monitoring, and managing study timelines and key milestones in Bioavailability/Bioequivalence (BA/BE) studies to ensure adherence to project deadlines, resource coordination, and regulatory deliverables.
Click to read the full article.

To define the procedure for establishing and maintaining an Electronic Trial Master File (eTMF) system for BA/BE studies, ensuring real-time documentation, compliance with ICH-GCP guidelines, and audit readiness.
Click to read the full article.

To establish a structured approach for the identification, assessment, documentation, and mitigation of project risks in Bioavailability/Bioequivalence (BA/BE) studies, ensuring study continuity, data integrity, and regulatory compliance.
Click to read the full article.

To define the process for registering BA/BE clinical trials in the European Clinical Trials Database (EudraCT) in accordance with European Medicines Agency (EMA) requirements for transparency, regulatory compliance, and study oversight.
Click to read the full article.

To define the process for implementing and ensuring compliance with the ICH E6(R2) Good Clinical Practice (GCP) Addendum requirements in Bioavailability and Bioequivalence (BA/BE) studies, with specific focus on quality management, sponsor oversight, and risk-based monitoring.
Click to read the full article.

To define the procedure for reviewing and aligning with current regulatory guidelines before the initiation of Bioavailability/Bioequivalence (BA/BE) studies to ensure protocol design, conduct, and reporting are compliant with applicable global regulations.
Click to read the full article.

To define the procedure for aligning Bioavailability/Bioequivalence (BA/BE) studies with global clinical development strategies, ensuring their timely inclusion in regulatory submissions, lifecycle planning, and multi-region product approvals.
Click to read the full article.

To define the procedure for preparing Bioavailability/Bioequivalence (BA/BE) studies for Good Clinical Practice (GCP) inspections and audits by regulatory authorities and independent quality teams, ensuring continuous readiness and compliance with applicable guidelines.
Click to read the full article.

To establish a standardized procedure for evaluating, documenting, and reviewing requests for bioequivalence (BE) waivers based on the Biopharmaceutics Classification System (BCS) Class I criteria in support of regulatory submissions.
Click to read the full article.

To establish a standardized and compliant process for receiving, evaluating, and responding to inquiries, clarification requests, and deficiency letters from regulatory agencies in relation to Bioavailability/Bioequivalence (BA/BE) studies.
Click to read the full article.